In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses how AbbVie is advancing the development of bispecific biologic therapies in both solid tumors and blood cancers.
Advancing Bispecific Biologic Therapies for Solid Tumors and Blood Cancers
Estimated read time
1 min read
+ There are no comments
Add yours